Novus Therapeutics is a pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat. Co. has two platform technologies, a surfactant and a foam. Co.'s primary program, OP0201, is a surfactant-based nasal aerosol drug-device combination product candidate being developed as a treatment option for patients at risk for, or with, otitis media (OM). OM is defined as middle ear inflammation and effusion with or without infection. Co. also has a foam-based drug delivery technology platform, which may be developed to deliver drugs into the ear, nasal, and sinus cavities. We show 16 historical shares outstanding datapoints in our coverage of NVUS's shares outstanding history.
Understanding the changing numbers of NVUS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NVUS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NVUS by allowing them to research NVUS shares outstanding history
as well as any other stock in our coverage universe. |
Free NVUS Email Alerts:
Video: Shares Outstanding Importance
